FDA Proposes Ban on Bulk Semaglutide and Tirzepatide Compounding
The FDA is considering tighter limits on compounded semaglutide and tirzepatide, raising questions about safety, access, cost, and the future of copycat GLP-1 weight loss and diabetes medications.